

Ronald G. Hall II, PharmD, MSCS

July 2025

Office (TTUHSC)

5920 Forest Park Rd.
Suite 400, Office #424
Dallas, Texas 75235
E-mail: ronald.hall@ttuhsc.edu
Phone: (214) 358-9009
Fax: (214) 654-9707

Home

4402 Firewheel Dr.
Garland, Texas 75044
hall2.ronald@gmail.com
(214) 236-4886

Current Positions

Faculty Appointment

9/09 **Associate Professor of Pharmacy Practice**
Clinical Sciences and Research Division
Texas Tech University Health Sciences Center, School of Pharmacy
Dallas, Texas
Tenure awarded 03/17

Administrative Appointments

1/23 **Chair**
Institutional Review Board #2 - 00000097
Texas Tech University Health Sciences Center
This IRB serves the Amarillo, Abilene, Dallas, and Permian Basin campuses of
TTUHSC as well as Angelo State University

9/22 **Director**
Clinical Pharmacology & Experimental Therapeutics Center
Texas Tech University Health Sciences Center
Jerry H. Hodge School of Pharmacy
School of Pharmacy
Dallas, Texas

10/17 **Division Head**
Clinical and Translational Science Division
Texas Tech University Health Sciences Center
Jerry H. Hodge School of Pharmacy
Dallas, Texas

8/09 **Director**
Dose Optimization and Outcomes Research (DOOR) Program
Dallas, Texas

Other Appointments

9/23 **Member**
Center of Excellence in Obesity and Cardiometabolic Research (formerly known
as the Obesity Research Institute)
Texas Tech University

9/22 **Leadership Team Member**
Center for Real-World Evidence
Texas Tech University Health Sciences Center
Jerry H. Hodge School of Pharmacy
Dallas, Texas

6/13 **Professional Affiliate**
Laura W. Bush Institute for Women's Health
Texas Tech University Health Sciences Center

Certification and Licensure

12/03 – 12/17 Board Certified Pharmacotherapy Specialist
Added Qualifications in Infectious Diseases (1/05-12/17)

8/02 – Present Registered Pharmacist, Texas

6/00 – 6/04 Registered Pharmacist, Tennessee

11/99 – Present Registered Pharmacist, Missouri

Education and Post-Graduate Training

7/06 – 6/09 **Master of Science in Clinical Sciences with distinction**
University of Texas Southwestern, Graduate School of Biomedical Sciences
Dallas, Texas

7/01 – 6/02 **ASHP Accredited Infectious Diseases Specialty Residency**
South Texas Veterans Health Care System
San Antonio, Texas

7/00 – 6/01 **ASHP Accredited Pharmacy Practice Residency**
Baptist Memorial Health Care
Memphis, Tennessee

8/99 – 5/00 **Doctor of Pharmacy**
Saint Louis College of Pharmacy
Saint Louis, Missouri

8/94 – 8/99 **Bachelor of Science - Pharmacy**
Saint Louis College of Pharmacy
Saint Louis, Missouri

Research Publications in Peer-Reviewed Journals (* = corresponding author)

1. *Hall RG 2nd, Liu S, Pai MP, et al. Impact of obesity on doxorubicin pharmacokinetics in women with breast cancer. J Oncol Pharm Pract. Published online March 13, 2025.
doi:10.1177/10781552251326045 PMID: 40080880.

2. Alvarez CA, **Hall RG 2nd**, Lin S, Perkins AR, Mortensen EM. Impact of PCV13 and PPSV23 Vaccination on Invasive Pneumococcal Disease in Adults with Treated Rheumatoid Arthritis: A Population-Based Study. *Microorganisms*. 2024 Oct 16;12(10):2073. <https://doi.org/10.3390/microorganisms12102073>
3. Johnson EG, Ortiz KM, Adams DT, Kaur S, Faust A, Yang H, Alvarez CA, **Hall RG 2nd**. A Retrospective Analysis of Intravenous Push Versus Extended Infusion Meropenem in Critically Ill Patients. *Antibiotics* 2024; 13(9):835. <https://doi.org/10.3390/antibiotics13090835>
4. Alvarez CA, **Hall RG 2nd**, Lin S, Perkins AR, Mortensen EM. Compliance with recommended pneumococcal vaccination schedule in patients treated for rheumatoid arthritis: A retrospective cohort study in the Veterans Affairs population. *Vaccine* 2024;42(3):489-495. <https://doi.org/10.1016/j.vaccine.2023.12.075>.
5. ***Hall RG 2nd**, Liu S, Putnam WC, Kallem R, Gumbo T, Pai MP. Optimizing anidulafungin exposure across a wide adult body size range. *Antimicrob Agents Chemother* 2023;67(11):e0082023. <https://doi.org/10.1128/aac.00820-23>
6. *Doan K, Appiah D, Aljanabi N, **Hall R**. Analysis of County-Level Pharmacist and Pharmacy Deserts in Texas. *WTJOM*. 2023;1(2):24-30. <https://westtexasjom.org/index.php/wtjm/article/view/17>
7. *Lee HS, Wagner JL, Vugrin M, Brandenburg RT, Lee J, Miller L, Rayborn S, **Hall RG 2nd**. Insufficient Representation of Patients with Obesity in Randomized Controlled Trials Evaluating the Efficacy and Safety of Antimicrobials for Treatment of Skin and Skin Structure Infections: A Scoping Review, *Open Forum Infect Dis*, 2023; ofad144, <https://doi.org/10.1093/ofid/ofad144>
8. *Farias-Ruiz C, Byrd TL, MacLaughlin EJ, **Hall RG 2nd**. Evaluation of scholarship motivators and barriers for non-tenure-track faculty in the Department of Pharmacy Practice. *Pharmacy* 2023; 11(1):31. <https://doi.org/10.3390/pharmacy11010031>
9. *Nguyen D, Selby AR, **Hall RG 2nd**. How Well Are Pharmacists Represented in National Institutes of Health R01 Funding to United States Schools of Pharmacy? *Pharmacy* 2022;10:165. <https://doi.org/10.3390/pharmacy10060165>
10. Buatois EM, Akunna AA, Bailey T, Coomer TN, Putnam WC, **Hall RG 2nd**, Pass SE, MacLaughlin EJ. Using the HyFlex Model to Deliver a Capstone Seminar Course for Fourth-Year Pharmacy Students. *Curr Pharm Teach Learn*. 2022 Sep;14(9):1109-1115. PMID: 36154956.
11. Blaszczyk AT, Sandlin K, Mirza S, Hernandez L, Bader H, **Hall RG**. Potential for Drug Interactions and Polypharmacy From Treatment of COVID-19 in Long-Term Care. *J Am Med Dir Assoc*. 2022 Jun;23(6):949-950. doi: 10.1016/j.jamda.2022.03.016. Epub 2022 Apr 6. PMID: 35504327; PMCID: PMC8983604.
12. ***Hall RG 2nd**, Cole TJ, Shaw C, Alvarez CA. The Risk of *Clostridioides difficile* Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts. *Antibiotics (Basel)*. 2022 Feb 23;11(3):295. doi: 10.3390/antibiotics11030295. PMID: 35326759; PMCID: PMC8944854.

13. Hawkins WA, Kim JY, Smith SE, Sikora Newsome A, **Hall RG**. Effects of Propofol on Hemodynamic Profile in Adults Receiving Targeted Temperature Management. *Hosp Pharm*. 2022 Jun;57(3):329-335. doi: 10.1177/00185787211032359. Epub 2021 Jul 11. PMID: 35615480; PMCID: PMC9125120.
14. *Selby AR, Raza J, Nguyen D, **Hall 2nd RG**. Potential Excess Intravenous Antibiotic Therapy in the Setting of Gram-Negative Bacteremia. *Pharmacy*. 2021;9(3):133. PMID: 34449693
15. Hawkins WA, Kim JY, Smith SE, Newsome AS, **Hall RG 2nd**. Effects of propofol on hemodynamic profile in adults receiving targeted temperature management. *Hosp Pharm* 2021 <https://doi.org/10.1177/00185787211032359> PMID: 35615480
16. Chen J, Patel TR, Pinho MC, Choi C, Harrison CE, Baxter JD, Derner K, Pena S, Liticker J, Raza J, **Hall RG**, Reed GD, Cai C, Hatanpaa KJ, Bankson JA, Bachoo RM, Malloy CR, Mickey BE, Park JM. Preoperative imaging of glioblastoma patients using hyperpolarized ¹³C pyruvate: Potential role in clinical decision making. *Neurooncol Adv*. 2021 Jun 28;3(1):vdab092. doi: 10.1093/noajnl/vdab092. PMID: 34355174; PMCID: PMC8331053.
17. Lee P, Fike D, Yang H, **Hall RG 2nd**, Pass S, Alvarez CA. Do the types and routes of proton pump inhibitor treatments affect *Clostridium difficile* in ICU patients? A retrospective cohort study. *Expert Rev Clin Pharmacol*. 2021 Mar;14(3):399-404. doi: 10.1080/17512433.2021.1890582. Epub 2021 Feb 28. PMID: 33576287.
18. Baruwal S, **Hall RG 2nd**, Pass SE, Safri A, Edwards KL. Efficacy and benefits of mock residency interviews. *Curr Pharm Teach Learn*. 2021 Aug;13(8):958-963. doi: 10.1016/j.cptl.2021.06.048. Epub 2021 Jul 3. PMID: 34294260.
19. Hackett EP, Pinho MC, Harrison CE, Reed GD, Liticker J, Raza J, **Hall RG**, Malloy CR, Barshikar S, Madden CJ, Park JM. Imaging Acute Metabolic Changes in Patients with Mild Traumatic Brain Injury Using Hyperpolarized [1-¹³C]Pyruvate. *iScience*. 2020 Nov 30;23(12):101885. doi: 10.1016/j.isci.2020.101885. PMID: 33344923; PMCID: PMC7736977.
20. Reed GD, Ma J, Park JM, Schulte RF, Harrison CE, Chen AP, Pena S, Baxter J, Derner K, Tai M, Raza J, Liticker J, **Hall RG 2nd**, Dean Sherry A, Zaha VG, Malloy CR. Characterization and compensation of *f₀* inhomogeneity artifact in spiral hyperpolarized ¹³C imaging of the human heart. *Magn Reson Med*. 2021 Jul;86(1):157-166. doi: 10.1002/mrm.28691. Epub 2021 Feb 5. PMID: 33547689; PMCID: PMC8049085.
21. Park JM, Reed GD, Liticker J, Putnam WC, Chandra A, Yaros K, Afzal A, MacNamara J, Raza J, **Hall RG**, Baxter J, Derner K, Pena S, Kallem RR, Subramanian I, Edpuganti V, Harrison CE, Muthukumar A, Lewis C, Reddy S, Unni N, Klemow D, Syed S, Li H, Cole S, Froehlich T, Ayers C, de Lemos J, Malloy CR, Haley B, Zaha VG. Effect of Doxorubicin on Myocardial Bicarbonate Production From Pyruvate Dehydrogenase in Women With Breast Cancer. *Circ Res*. 2020 Dec 4;127(12):1568-1570. doi: 10.1161/CIRCRESAHA.120.317970. Epub 2020 Oct 14. PMID: 33054563.

22. Putnam WC, Kallem RR, Edpuganti V, Subramaniyan I, **Hall RG 2nd**. Development and validation of a quantitative LC-MS/MS method for the simultaneous determination of ceftolozane and tazobactam in human plasma and urine. *J Chromatogr B* 2020;1159(30):122354. PMID: 32905989
23. *John J, Perry G, Perry J, Guttenberg V, Asonganyi N, Laheji S, Raza J, **Hall RG**. Impact of Neostigmine and Sugammadex on Time to Leaving the Operating Room in a Community Hospital. *Innov Pharm*. 2020 Jul 31;11(3). doi: 10.24926/iip.v11i3.3329. PMID: 34007641.
24. Blaszczyk AT, Anderson SS, **Hall RG 2nd**. Appropriateness of Fluoroquinolone Prescribing in the Long-Term Care Setting. *J Am Geriatr Soc* 2020;68(3):661-3. PMID: 31922257
25. Rutter WC, **Hall RG**, Burgess DS. Impact of total body weight on acute kidney injury incidence among patients treated with piperacillin-tazobactam and vancomycin. *Am J Health Syst Pharm* 2019;76(16):1211-7. PMID: 31369116
26. ***Hall RG 2nd**, Yoo E, Faust A, Smith T, Goodman E, Mortensen EM, Raza J, Dehmami F, Alvarez CA. Impact of Piperacillin/Tazobactam on Nephrotoxicity in Patients with Gram-negative Bacteremia. *Int J Antimicrob Agents* 2019;53:343-6. PMID: 30415001
27. ***Hall RG 2nd**, Yoo E, Faust A, Smith T, Goodman E, Mortensen EM, Felder V, Alvarez C. Impact of total body weight on acute kidney injury in patients with gram-negative bacteremia. *Expert Rev Clin Pharmacol* 2018;11:651-4. PMID: 29718754
28. **Hall RG 2nd**, Pasipanodya JG, Swancutt MA, Meek C, Leff R, Gumbo T. Supervised-machine learning reveals that old and obese people achieve low dapson concentrations. *CPT Pharmacometrics Syst Pharmacol* 2017;6:552-599. PMID: 28575552
29. ***Hall RG 2nd**, Yoo E, Faust A, Smith T, Goodman E, Mortensen EM, Richardson S, Alvarez C. Impact of total body weight on 30-day mortality in patients with gram-negative bacteremia. *Expert Rev Anti Infect Ther* 2017;15:797-803. PMID: 28481638
30. Lee GC, **Hall RG**, Boyd NK, Dallas SD, Du LC, Treviño LB, Retzlöff C, Treviño SB, Lawson KA, Wilson J, Olsen RJ, Wang Y, Frei CR. A prospective observational cohort study in primary care practices to identify factors associated with treatment failure in *Staphylococcus aureus* skin and soft tissue infections. *Ann Clin Microbiol & Antimicrob* 2016;15:58. PMID: 27876059
31. **Hall RG 2nd**, Pasipanodya JG, Meek C, Leff RD, Swancutt M, Gumbo T. Fractal geometry based decrease in trimethoprim-sulfamethoxazole concentrations in overweight and obese people. *CPT Pharmacometrics Syst Pharmacol* 2016;5:674-81. PMID: 27869362
32. Lee GC, **Hall RG**, Boyd NK, Dallas SD, Du LC, Treviño LB, Retzlöff C, Treviño SB, Lawson KA, Wilson J, Olsen RJ, Wang Y, Frei CR. Predictors of community-associated *Staphylococcus aureus* methicillin resistant- and methicillin susceptible *Staphylococcus aureus* skin and soft tissue infections in the primary care setting. *Epidemiol Infect*. 2016;144(15):3198-3204 PMID: 27489019
33. Pasipanodya J, **Hall RG**, Gumbo T. In silico-derived formula for individualized micafungin dosing for obese patients in the age of deterministic chaos. *Clin Pharmacol & Ther* 2015;97:292-7. PMID: 25670351

34. ***Hall RG**, Blaszczyk AT, Thompson KA, Brouse SD, Giuliano CA, Frei CR, Forcade NA, Mortensen EM, Bell T, Bedimo RJ, Alvarez CA. Impact of empiric weight-based vancomycin dosing on nephrotoxicity and mortality in geriatric patients with methicillin-resistant *Staphylococcus aureus* bacteremia. J Clin Pharm Ther 2014;39:653-7. PMID: 25200273
35. *Alvarez CA, Giuliano CA, Haase KK, Thompson KA, Frei CR, Forcade NA, Brouse SD, Mortensen EM, Bell T, Bedimo RJ, Toups NM, **Hall RG**. Dosing vancomycin in intensive care unit patients with methicillin-resistant *Staphylococcus aureus* bacteremia. Am J Med Sci 2014;348:371-6. PMID: 24762747
36. Pusch T, Pasipanodya J, **Hall R**, Gumbo T. Therapy duration and long-term outcomes in extra-pulmonary tuberculosis. BMC Infect Dis 2014;14:115. PMID: 24580808 (highly accessed; >1,000 accesses and downloads first month)
37. ***Hall RG**, Swancutt MA, Meek C, Leff R, Gumbo T. Weight drives caspofungin variability in overweight and obese people: fractal power signatures beyond 2/3 or 3/4. Antimicrob Agents Chemother 2013;57:2259-64. PMID: 23459494
38. ***Hall RG**, Hazlewood KA, Brouse SD, Giuliano CA, Haase KK, Frei CR, Forcade NA, Bell T, Bedimo RJ, Alvarez CA. Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant *Staphylococcus aureus* bacteremia: a retrospective cohort study. BMC Pharmacol Toxicol 2013;14:12. PMID: 23402420
39. ***Hall RG**, Giuliano CA, Haase KK, Hazlewood KA, Frei CR, Forcade NA, Brouse SD, Bell T, Bedimo RJ, Alvarez CA. Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant *Staphylococcus aureus* bacteremia: a retrospective cohort study. BMC Infect Dis 2012;12(1):104. PMID: 22540223 (highly accessed; >1,000 accesses and downloads first month)
40. ***Hall RG**, Swancutt MA, Meek C, Leff R, Gumbo T. Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. Antimicrob Agents Chemother 2012;56(3):1502-7. PMID: 22155817
41. **Hall RG**, Swancutt M, Gumbo T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother 2011;55(11):5107-12. PMID: 21876061
42. Lopes-Serrao MD, Gressett S, **Hall R**, Shah S. An evaluation of the incidence of myelosuppression in obese patients with a capped body surface area. J Oncol Pract 2011;7(1):13-7 PMID: 21532803 [accompanied by an editorial].
43. ***Hall RG**, Payne KD, Bain AM, Rahman AP, Nguyen ST, Eaton SA, Busti AJ, Vu SL, Bedimo R. Multicenter evaluation of vancomycin dosing – emphasis on obesity. Am J Med 2008;121:515-8. PMID: 18501233 ([ReachMD interview](#))
44. ***Hall RG**, Shah SR, Villela LR, Amirkhan RH. The impact of inadequate empiric therapy on clinical outcomes of patients with *Escherichia coli* or *Klebsiella species* bacteremia. J Pharm Practice 2007;20(5):392-8.

45. Busti AJ, Bain AM, **Hall RG**, Bedimo RG, Leff RD, Meek C, Mehvar R. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. *J Cardiovasc Pharmacol* 2008;51(6):605-10. PMID: 18520949
46. Burgess DS, **Hall RG**. Simulated comparison of ciprofloxacin and levofloxacin pharmacodynamics against *Pseudomonas aeruginosa* using healthy volunteer pharmacokinetic and 2002 minimum inhibitory concentration (MIC) data. *Clin Ther* 2007;29(7):1421-7. PMID: 17825693
47. Burgess DS, **Hall RG**. In vitro activity of parenteral β -lactams, levofloxacin and tobramycin alone or in combination against extended-spectrum β -lactamase producing *Klebsiella pneumoniae*. *Int J Antimicrob Agents* 2004;24:48-52. PMID: 15225861
48. Burgess DS, **Hall RG**. In vitro activity of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing *Klebsiella pneumoniae*. *Diagn Microbiol Infect Dis* 2004;49(1):41-6. PMID: 15135499
49. Burgess DS, **Hall RG**, Lewis JS, Jorgensen JH, Patterson JE. Outcomes of patients infected with extended-spectrum beta-lactamase (ESBL) producing bacteria at a university hospital. *Pharmacotherapy* 2003;23(10):1232-7. PMID: 14594340
50. Burgess DS, **Hall RG**, Hardin TC. *In vitro* evaluation of the activity of two doses of levofloxacin alone and in combination with other agents against *Pseudomonas aeruginosa*. *Diagn Microbiol Infect Dis* 2003;46(2):131-7. PMID: 12812717

Review Articles in Peer-Reviewed Journals (* = corresponding author)

51. Bainum TB, Reveles KR, **Hall RG**, Cornell K, Alvarez CA. Controversies in the prevention and treatment of *Clostridioides difficile* infection: A narrative review. *Microorganisms* 2023;11(2):387. <https://doi.org/10.3390/microorganisms11020387>
52. Clifford KM, Selby, AR, Reveles KR, Teng C, **Hall RG 2nd**, McCarrell J, Alvarez CA. The Risk and Clinical Implications of Antibiotic-Associated Acute Kidney Injury: A Review of the Clinical Data for Agents with Signals from the FAERS Database. *Antibiotics* 2022;11:1367. <https://doi.org/10.3390/antibiotics11101367>
53. McCarrell JL, Bailey TA, Duncan NA, Covington LP, Clifford KM, **Hall RG**, Taggart Blaszczyk A. A review of citalopram dose restrictions in the treatment of neuropsychiatric disorders in older adults. *Ment Health Clin [Internet]*. 2019;9(4):280-6. DOI: 10.9740/mhc.2019.07.280.
54. Selby A, **Hall RG 2nd**. Utilizing the Patient Care Process to Minimize the Risk of Vancomycin-Associated Nephrotoxicity. *J Clin Med* 2019;8:E781. PMID: 31159415 (Dr. Selby won the TTUHSC Jerry H. Hodge School of Pharmacy, Pharmacy Practice Non-tenure track Paper of the Year for this publication)
55. ***Hall RG 2nd**, Smith WJ, Putnam WC, Pass SE. An evaluation of tedizolid for the treatment of MRSA infections. *Expert Opin Pharmacother* 2018;19:1489-94. PMID: 30200779
56. Payne KD, Das A, Ndiulor M, **Hall RG 2nd**. Dosing strategies to optimize currently available anti-MRSA treatment options (Part 2: PO options). *Expert Rev Clin Pharmacol* 2018;11:139-149. PMID: 29186999

57. *Hall RG 2nd, Thatcher M, Wei W, Varghese S, Varughese L, Ndiulor M, Payne K. Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options). *Expert Rev Clin Pharmacol* 2017;10:493-508. PMID: 28293964
58. *Minze MG, Kwee YY, Hall RG. Low-molecular-weight heparin prophylaxis dosing: Is weight an issue?. *J Pharm Technol* 2016;32:75-80.
59. *Payne K, Hall RG. Dosing of antifungals in obesity. *Expert Rev Anti Infect Ther* 2016;14:257-67. PMID: 26641135
60. *Hall RG. Evolving larger. Dosing anti-tuberculosis (TB) drugs in an obese world. *Curr Pharm Des* 2015;21:4748-51. PMID: 26112269
61. *Lee YR, Hougue C, Hall RG. Treatment of community-acquired pneumonia. *Expert Rev Anti Infect Ther* 2015;19:1-13. PMID: 26091895
62. *Hall RG & Michaels HN. Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infections. *Infect Drug Resist* 2015;8:75-82. PMID: 25960671
63. *Payne KD & Hall RG. Dosing of antibacterial agents in obese adults: Does one size fit all?. *Expert Rev Anti Infect Ther* 2014;12(7):829-54. PMID: 24809811
64. *Hall RG, Jean GW, Sigler M, Shah S. Dosing considerations for obese patients receiving cancer chemotherapeutic agents. *Ann Pharmacother* 2013;47(12):1666-74. PMID: 24259627
65. *Cooper T, Brouse S, Pass S, Hall RG. Achieving positive outcomes in multi-drug resistant *Acinetobacter* infections: Dose optimization by pharmacokinetic and pharmacodynamic principles. *Ann Pharmacother* 2011;45:229-40. PMID: 21304038
66. *Arnold A, Brouse SD, Pitcher WD, Hall RG. Empiric therapy for gram-negative pathogens in nosocomial and health-care associated pneumonia: Starting with the end in mind. *J Int Care Med* 2010;25:259-70. PMID: 20622257
67. *Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: Grave concern or death by character assassination? *Am J Med* 2010;123:182.e1-182.e7. PMID: 20103028
68. *Giuliano C, Haase KK, Hall R. Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections. *Expert Rev Anti Infect Ther* 2010;8(1):95-106. PMID: 20014904
69. *Hall RG, Leff RD, Gumbo T. Treatment of active pulmonary tuberculosis in adults: Current standards and recent advances: Insights from the Society of Infectious Diseases Pharmacists. *Pharmacotherapy* 2009;29(12):1468-81. PMID: 19947806
70. *Maclayton DO, Hall RG. Pharmacologic options for the treatment of methicillin-resistant *Staphylococcus aureus* (MRSA) nosocomial pneumonia. *Ann Pharmacother* 2007;41:235-44. PMID: 17299012

71. Busti AJ, **Hall RG**, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. *Pharmacotherapy* 2004;24(12):1732-47. PMID: 15585441

Miscellaneous Publications in Peer-Reviewed Journals (* = corresponding author)

72. Craddock DS, **Hall RG**. Pharmacists without Access to the EHR: Practicing with One Hand Tied Behind Our Backs. *Innov Pharm*. 2021 Jun 10;12(3):10.24926/iip.v12i3.4141. doi: 10.24926/iip.v12i3.4141. PMID: 35601575; PMCID: PMC9119989.
73. Lodise TP, **Hall RG 2nd**, Scheetz MH. Vancomycin Area Under the Curve-guided Dosing and Monitoring: "Is the Juice Worth the Squeeze"? *Pharmacotherapy*. 2020 Dec;40(12):1176-1179. doi: 10.1002/phar.2482. PMID: 33368454.
74. ***Hall RG**, Foslein-Nash C, Singh DK, Zeiss RA, Sanders KM, Patry R, Leff R. A formalized teaching, practice, and research partnership with the Veterans Affairs North Texas Health Care System: A model for advancing academic practice partnerships. *Am J Pharm Educ* 2009;73(8) Article 141. PMID: 20221334
75. Nguyen ST, Bain AM, Bedimo RG, **Hall RG**, Busti A. Acute elevation of triglycerides after initiation of fosamprinavir/ritonavir in an HIV-negative patient with baseline hypertriglyceridemia. *J Clin Lipid* 2008;2(5):398-400. PMID: 21291769
76. Edwards KL, **Hall RG**, Ceja ME. Gatifloxacin-induced hyperglycemia: Report of four cases and a review of the literature. *J Pharm Practice* 2007;20(1):93-102.

Book Chapters (* = corresponding author)

77. Pasipanodya J, **Hall R**, Gumbo T. Tuberculosis and Other Mycobacterial Diseases. In: Bope ET, Rakel RE, Kellerman R, eds. *Conn's Current Therapy 2010-2019*. Philadelphia, PA: Elsevier Inc.
78. ***Hall RG**. Nosocomial Pneumonia. In: Cheng JWM, Chessman KH, Hume AL et al., eds. *Pharmacotherapy Self-Assessment Program*, 6th ed. Infectious Diseases Module. Lenexa, KS: American College of Clinical Pharmacy;2008:109-26.
79. Burgess DS & **Hall RG**. Aztreonam. In: Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, eds. *Antimicrobial Therapy and Vaccines*. 2nd ed. Pittsburgh, PA: ESun Technologies, LLC;2005:45-54 (Vol. 2).

Platform Presentation Abstracts

International

1. Hawkins WA, Branam TN, Stitt TM, **Hall RG 2nd**. Dosing of Thromboprophylaxis by Various Anthropometric Stratification: Are We Missing the Mark? (Abstract 480) Society of Critical Care Medicine 2019 Critical Care Congress, San Diego, California, 2/19. *Crit Care Med*. 2019;47(1):220.
2. **Hall RG**, Meek C, Swancutt M, Leff R, Gumbo T. A surprising effect of weight on ethambutol (EMB) pharmacokinetics (PK). 3rd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Boston, Massachusetts, 9/10.

National

3. Lee P, Fike D, **Hall R**, Pass S, Alvarez C. Do the types and routes of proton pump inhibitor treatments affect *Clostridium difficile* in ICU patient? (Abstract 42767). American College of Clinical Pharmacy Annual Meeting, Phoenix, Arizona, 10/17. *Pharmacotherapy* 2017;37(12):E201. (Best student poster finalist)
4. Gressett S, Lopes-Serraio M, **Hall R**, Shah S. An evaluation of myelosuppression in obese patients with a capped BSA. *J Oncol Pharm Practice*. 2010;16(S1):abst# P2.
5. Busti AJ, Bain AM, **Hall RG**, Bedimo R, Leff R, Meek C, Mehvar R. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. 2008 National Lipid Association Annual Scientific Sessions, Seattle WA, 5/29 – 6/1 2008. *J Clin Lipid* 2008;2:202.
6. Villela LR, **Hall RG**, Amirkhan RH. Does Fluoroquinolone Resistance Affect the Clinical Outcomes of Patients with *Escherichia coli* or *Klebsiella species* Bacteremia? (Abstract #122). American College of Clinical Pharmacy Annual Meeting, Dallas, Texas, 10/04. *Pharmacotherapy* 2004;24:1440.

Poster Presentation AbstractsInternational

1. Stitt TM, Hawkins WA, **Hall RG 2nd**. Prevalence and risk factors of inappropriate dosing of pharmacologic thromboprophylaxis during critical illness. Global Meeting of the American College of Clinical Pharmacy, Seattle, Washington, 10/18
2. Floris L, Curtis J, Hawkins WA, **Hall R**. Effect of Comorbidities on Fluid Resuscitation in patients with sepsis or shock. Global Meeting of the American College of Clinical Pharmacy, Seattle, Washington, 10/18
3. Hager J, Clifford KM, **Hall RG**. Identifying incidence and outcomes of sepsis in the pediatric population in the United States. Global Meeting of the American College of Clinical Pharmacy. Seattle, Washington. 10/18.
4. Jacob J, Clifford KM, **Hall RG**. Exploring the prevalence of diabetes mellitus, chronic kidney disease, or both in adults with sepsis and impact on mortality. Global Meeting of the American College of Clinical Pharmacy. Seattle, Washington. 10/18.
5. Wilson S, Clifford KM, **Hall RG**. Identifying sepsis-related mortality in the older adult population. Global Meeting of the American College of Clinical Pharmacy. Seattle, Washington. 10/18.
6. Vetteythadathil J, Clifford KM, **Hall RG**. Identifying trends in sepsis incidence by race. Global Meeting of the American College of Clinical Pharmacy. Seattle, Washington. 10/18.
7. McKinney Z, Clifford KM, **Hall RG**. Mortality Rates of AIDS-Defining opportunistic illnesses in hospitalized patients with HIV in the US. Global Meeting of the American College of Clinical Pharmacy. Seattle, Washington. 10/18.
8. Alvarez CA, Lee P, Fike D, Mortensen E, Pass SE, **Hall RG**. Association of the number of antibiotics received and *Clostridium difficile* infection among patients admitted to the intensive

care unit. 33rd International Conference for Pharmacoepidemiology (ICPE), Montreal, Canada, 8/17. Pharmacoepi Drug Safety. 2017;26:346-7.

9. **Hall RG**, Yoo E, Faust A, Goodman E, Richardson S, Alvarez CA. Impact of increased patient weight on 30-day mortality in patients with gram-negative bacteremia (Abstract #K-101). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/International Congress of Chemotherapy and Infection (ICC), San Diego, California, 9/15 (Interviewed for an article in Internal Medicine News)
10. **Hall RG**, Pasipanodya JG, Swancutt MA, Meek C, Leff RD, Gumbo T. Machine learning reveals that old and obese people achieve low dapsons concentrations (Abstract #A1-004). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/International Congress of Chemotherapy and Infection (ICC), San Diego, California, 9/15
11. Pasipanodya JG, **Hall R**, Narendran G, McIlleron H, Magazi B, Srivastava S, Deshpande D, Swaminathan S, Gumbo T (Abstract #P-106). Emergence of drug resistant tuberculosis is a stochastic Levy process: The end of doublespeak and doublethink! (Abstract #P-106). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/International Congress of Chemotherapy and Infection (ICC), San Diego, California, 9/15
12. **Hall RG**, Giuliano CA, Haase KK, Hazlewood KA, Frei CR, Forcade NA, Brouse SD, Mortensen EM, Bell T, Bedimo RJ, Touns NM, Alvarez CA. Impact of empiric weight-based vancomycin dosing on nephrotoxicity and mortality in ICU patients with MRSA bacteremia (Abstract #K-708). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver, Colorado, 9/13.
13. Pusch T, Pasipanodya JG, **Hall RG**, Gumbo T. Optimal therapy duration and long-term outcomes in extra-pulmonary tuberculosis (Abstract #L-1337). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Denver, Colorado, 9/13.
14. Pasipanodya JG, Pusch T, **Hall RG**, Gumbo T. Patients successfully treated for tuberculosis (TB) have poor long-term survival despite completion of directly observed therapy, short course (DOTS) (Poster P9). 46th Tuberculosis and Leprosy Research Conference, Saitama, Japan, 12/11.
15. Giuliano C, Haase K, Hazelwood K, Alvarez C, Frei C, Forcade N, Brouse S, Bell T, Bedimo R, **Hall R**. A multi-center study evaluating the impact of guideline-recommended empiric dosing of vancomycin in MRSA bacteremia (Abstract #K-309). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, Massachusetts, 9/10.
16. **Hall RG**, Meek C, Swancutt M, Leff R, Gumbo T. A surprising effect of weight on ethambutol (EMB) pharmacokinetics (PK) (Abstract #A1-058). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Boston, Massachusetts, 9/10.
17. Forcade NA, **Hall RG**, Brouse SD, Giuliano C, Hazelwood K, Haase K, Frei CR. Comparison of health outcomes and nephrotoxicity for diabetic and non-diabetic patients hospitalized for MRSA bacteremia. Fifth Decennial International Conference on Healthcare-Associated Infections. Atlanta, GA, 3/10.

18. Pasipanodya J, **Hall R**, Weis S, Gumbo T. Fat, fractals, and failure of antituberculosis pharmacotherapy (Abstract #L1-1660). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, 9/09.
19. **Hall RG** & Revankar SG. Time to Positivity of Candida Blood Cultures (Abstract #M-263). Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, 10/04.

National

20. Gorczyca H, Alvarez CA, Vu C, **Hall RG 2nd**. Incidence of Acute Kidney Injury with Imipenem-Cilastatin vs. Meropenem in Patients with Pneumonia, Bacteremia, and/or Sepsis: A Retrospective, Cohort Study. American College of Clinical Pharmacy Annual Meeting, Phoenix, AZ, 10/24.
21. Stark HN, Bainum TB, Buatois EM, Charlton AN, **Hall RG 2nd**, Mantzke CM, Haase KK. Factors associated with second-dose delays and overlaps of antibiotics in sepsis. American College of Clinical Pharmacy Annual Meeting, Dallas, TX, 10/23.
22. **Hall RG 2nd**, Shaw C, Cole TJ, Alvarez CA. Evaluation of Disparities in Beta-Lactam Allergies and Subsequent Antibiotic Use in Outpatients with Acute Bacterial Skin and Skin Structure Infections. , *Open Forum Infectious Diseases*, Volume 10, Issue Supplement_2, December 2023, ofad500.1666, <https://doi.org/10.1093/ofid/ofad500.1666> Presented at ID Week, Boston, Massachusetts, 10/23.
23. Lee HS, Lee J, **Hall R**, Vugrin M. Do Randomized Control Trials Evaluating Systemic Antimicrobials for Treatment of Bacterial Skin and Soft Tissue Represent the Current United States Demographics?: A Scoping Review. (Abstract 1359384) ASHP Midyear Clinical Meeting, Las Vegas, Nevada, 12/22
24. Gehrlein M, Bae E, **Hall R**, Spitznogle S. Characterization of Fosfomycin Use at Outpatient Clinics at an Academic Medical Center. (Abstract 1361661) ASHP Midyear Clinical Meeting, Las Vegas, Nevada, 12/22
25. Doan K, Appiah D, Aljanabi N, **Hall R**. Evaluating Practice Locations of Texas Tech University Health Sciences Center Jerry H. Hodge School of Pharmacy Graduates on Access to Community Pharmacy Services in Texas. (Abstract 1361121) ASHP Midyear Clinical Meeting, Las Vegas, Nevada, 12/22
26. Riofta M, **Hall R**. A Systematic Review of Randomized Controlled Trials for Weight-based Outcomes in the Treatment of Invasive Candidiasis. ASHP Midyear Clinical Meeting, Virtual (COVID-19), 12/21.
27. **Hall R**, Selby A, Khan N, Dadashian T. Evaluation of Therapeutic Efficacy of Weight-Based versus Non-Weight-Based Dosing of Norepinephrine in a Cardiopulmonary ICU. ASHP Midyear Clinical Meeting, Virtual (COVID-19), 12/21.
28. Miller LE, Rayborn SA, **Hall RG**, Wagner JL. Are people with obesity represented in randomized controlled trials evaluating systemic antimicrobials for treatment of acute bacterial skin and skin

structure infections?: A systematic review. American College of Clinical Pharmacy Annual Meeting, Virtual (COVID-19), 10/21.

29. Buatois EM, Akunna AA, Bailey T, Coomer TN, Putnam WC, **Hall RG**, Pass SP, MacLaughlin EJ. Using a Hyflex model to deliver a capstone seminar course. Abst#57732. American College of Clinical Pharmacy Annual Meeting, Virtual (COVID-19), 10/21. (First place poster in the Education and Training Practice and Research Network meeting)
30. Doles H, **Hall RG**. Pharmacists and National Institutes of Health R01 funding at United States Schools of Pharmacy (Abstract SP-349). ASHP Midyear Clinical Meeting, Virtual (COVID-19), 12/20.
31. **Hall RG**, Pasipanodya JG, Griswold J, Dissanaik S, Putnam WC, Kallem RR, Edpuganti V, Subramaniyan I. Pharmacokinetics of Ceftolozane/Tazobactam in Patients with Burns (Abstract 1319). Open Forum Infectious Diseases, Volume 7, Issue Supplement_1, October 2020, Pages S670–S671, <https://doi.org/10.1093/ofid/ofaa439.1501> Presented at ID Week, Virtual Conference (COVID-19), 10/20.
32. Baruwal S, **Hall R**, Pass S, Edwards KL. Efficacy and benefits of mock residency interviews. ASHP Midyear Clinical Meeting, Las Vegas, Nevada, 12/19.
33. Anderson SS, Blaszczyk AT, **Hall RG**. Appropriateness of fluoroquinolone prescribing in the long-term care setting. Senior Care Pharmacist. 2019;34(9):548-579.
34. Hawkins AW, Kim YJ, Smith SE, Sikora Newsome A, **Hall R**. Hemodynamic effects of propofol during targeted temperature management after cardiac arrest. American College of Clinical Pharmacists (ACCP) Annual Meeting, New York, New York, 10/19 Published in J Amer Coll Clin Pharm 2019;3:174-5.
35. Nguyen N, **Hall R**, Raza J. Are trials of systemic antibiotic for skin infections representative of patients in the United States of America? A systemic review of double-blind randomized control trials. ASHP Midyear Clinical Meeting, Anaheim, California, 12/18
36. Raza J, Yoo ED, Faust A, Alvarez CA, **Hall RG 2nd**. Impact of Piperacillin/Tazobactam on Nephrotoxicity in Patients with Gram-negative Bacteremia. ASHP Midyear Clinical Meeting, Anaheim, California, 12/18
37. Laheji S, Raza J, John J, Perry G, **Hall RG 2nd**. Impact of neostigmine and sugammadex on time to leaving the operating room in a community hospital. ASHP Midyear Clinical Meeting, Anaheim, California, 12/18
38. Lee P, Fike D, **Hall R**, Pass S, Alvarez C. Do the types and routes of proton pump inhibitor treatments affect Clostridium difficile in ICU patient? (Abstract 369280). American Society of Health-System Pharmacists Midyear Clinical Meeting, Orlando, Florida, 12/17. (Encore)
39. Lee P, Fike D, **Hall R**, Pass S, Alvarez C. Do the types and routes of proton pump inhibitor treatments affect Clostridium difficile in ICU patient? (Abstract 42767). American College of Clinical Pharmacy Meeting, Phoenix, Arizona, 10/17. (Best student poster finalist)

40. Rutter WC, **Hall R**, Burgess DS. Impact of obesity on acute kidney injury incidence among patients treated with piperacillin-tazobactam and vancomycin (Abstract 66398). ID Week, San Diego, California, 10/17. Open Forum Infectious Diseases 2017;4:S336.
41. Richardson S, Yoo E, Alvarez C, Faust A, **Hall R**. Factors independently associated with all-cause 30-day mortality in patients with gram-negative bacteremia (Abstract 3-362). American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, 12/15.
42. Felder V, Yoo E, Alvarez C, Faust A, **Hall R**. Impact of increased total body weight on the occurrence of nephrotoxicity in patients with gram-negative bacteremia (Abstract 3-339). American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, Louisiana, 12/15.
43. Meek C, Miingi N, Beck E, **Hall R**, Leff R. An analytical method of automated analysis of plasma dapsone, trimethoprim, sulfamethoxazole, sulfamethazine, sulfamethizole, and sulfathiazole for dose optimization (Abstract 1246). American Society of Mass Spectrometry Conference, Baltimore, Maryland, 6/14.
44. Meek C, Beck E, **Hall R**, Leff R. Determination of plasma caspofungin content using tandem mass spectrometry (LC-MS/MS): An accurate, precise, selective and sensitive method (Abstract 2545). 60th American Society of Mass Spectrometry Conference, Vancouver, Canada, 05/12.
45. Gower J, Meek C, **Hall R**, and Leff R. Effect of Obesity on Caspofungin Pharmacokinetics. ASHP Midyear Clinical Meeting, New Orleans, Louisiana, 12/11.
46. Hazelwood K, Brouse SD, Giuliano C, Alvarez C, Frei CR, Forcade N, Haase KK, Bedimo R, Bell T, **Hall RG**. A multi-center study evaluating the impact of IDSA guideline-recommended empiric dosing on nephrotoxicity. Infectious Diseases Society of America Meeting, Vancouver, Canada, 10/10.
47. Anderson G, **Hall R**, Stoll J, Nelson AA. Comparison of OSCE absolute criteria reliability established using the Angoff and borderline group regression procedures. American Association of Colleges of Pharmacy Annual Meeting. Seattle, Washington, 7/10.
48. Hazlewood KA, **Hall RG**, Brouse SD, Duquaine SM, Bedimo R. Effect of guideline recommended vancomycin dosing on nephrotoxicity rates in patients with MRSA bacteremia (Abstract #956). Society of Critical Care Medicine's 39th Critical Care Congress. Miami, Florida, 1/10.
49. Hooper JS, **Hall RG**, Busti AJ, Hasan MS, Hartless K. Is obesity a risk factor for the development of surgical site infections? (Abstract #216). American College of Clinical Pharmacy Spring Forum, Myrtle Beach, South Carolina, 4/05. Pharmacotherapy 2005;25:485.
50. Brouse SD, Vu KL, **Hall RG**, Pitcher D. Time to resolution of ventilator-associated pneumonia (Abstract #407). 34th Critical Care Conference, Phoenix, Arizona, 1/05. Crit Care Med;32(12 Suppl.):A112.
51. Burgess DS, **Hall RG**. Impact of ESBL Enzyme and Inoculum Size on Antimicrobial Activity as Measured by Time-kill Methodology (Abstract #133). American College of Clinical Pharmacy Annual Meeting, Dallas, Texas, 10/04. Pharmacotherapy 2004;24:1441.

52. Cox CD, Stanford BL, Brouse S, Haase KK, Akins RL, Bowie VL, Tsikouris JP, Busti AJ, Shah S, **Hall R**, Burleson B, and Seifert CF. Validation of an experiential teaching peer assessment tool (Abstract #62). American College of Clinical Pharmacy Annual Meeting, Dallas, Texas, 10/04. *Pharmacotherapy* 2004;24:1430.
53. Burgess DS, **Hall RG**. Evaluation of current NCCLS breakpoints for extended-spectrum cephalosporins against Gram-negative bacteria based on pharmacodynamic principles (Abstract #129). American College of Clinical Pharmacy Meeting, Atlanta, Georgia, 11/03. *Pharmacotherapy* 2003;23(10):1347-8.
54. Burgess DS, **Hall RG**. In vitro killing of ertapenem compared to several other antimicrobials against extended-spectrum β -lactamase *K. pneumoniae* (Abstract #128). American College of Clinical Pharmacy Meeting, Atlanta, Georgia, 11/03. *Pharmacotherapy* 2003;23(10):1347.
55. Cox CD, Stanford BL, Brouse S, Seifert CF, Haase KK, Akins RL, Bowie VL, Tsikouris JP, Busti AJ, Shah S, **Hall R**. Development of an Experiential Teaching Assessment Tool (Abstract #57). American College of Clinical Pharmacy Meeting, Atlanta, Georgia, 11/03. *Pharmacotherapy* 2003;23(10):1336.
56. Greene J, Roberts K, **Hall RG**, Amirkhan R. A retrospective, cohort analysis of antimicrobial prescribing in the management of gram-negative pathogens in the ICU. 37th Annual American Society for Health-Systems Pharmacists Midyear Clinical Meeting, Atlanta, Georgia, 12/02.
57. Burgess DS, **Hall RG**, Lewis JS, Jorgensen JH, Patterson JE. Outcomes of patients infected with extended-spectrum beta-lactamase (ESBL) producing bacteria at a university hospital (Abstract #202). Infectious Diseases Society of America Meeting, Chicago, Illinois, 10/02.
58. Burgess DS, **Hall RG**. Levofloxacin low dose (500 mg) and high dose (750 mg) alone and in combination against *P. aeruginosa*. American College of Clinical Pharmacy Spring Forum, Atlanta, Georgia, 4/02.
59. **Hall RG**, Kuhl D, Windisch P, Morton T. Multi-hospital evaluation of fluoroquinolone use. 35th Annual American Society for Health-Systems Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, 12/00.

Grantsmanship

1. Date: 10/23-9/24 Source: TTUHSC Disparities Seed Grant Program
 Title: Evaluation of Potential Disparities in the Treatment of Candidemia in Obese Patients
 Total costs: \$6,500
 Role: Co-investigator % Effort: 5% PI: Ashley Selby
 Collaborators: Ashley Selby, PharmD, Taryn Bainum, PharmD, Chip Shaw, PhD, Travis Cole
2. Date: 10/23-9/24 Source: Merck & Co., Inc.
 Title: A retrospective cohort study using Cerner Health Facts to evaluate the use of ceftolozane/tazobactam in patients with bacteremia due to gram-negative pathogens
 Total costs: \$172,800
 Role: PI % Effort: 10% PI: Hall
 Collaborators: Carlos Alvarez, PharmD, MSc, MSCS
3. Date: 10/22-9/23 Source: TTUHSC Disparities Seed Grant Program

Title: Evaluation of Potential Disparities in the Outpatient Treatment of Skin and Soft Tissue Infections

Total costs: \$10,000

Role: PI % Effort: 5% PI: Hall

Collaborators: Chip Shaw, PhD, Travis Cole

4. Date: 9/21-8/26 Source: Cancer Prevention & Research Institute of Texas
 Title: North Texas Clinical Pharmacology Cancer Core
 Total costs: \$2,965,226
 Role: Co-investigator (1/21-8/22; 1/24-Present) % Effort: 5% PI: Trey Putnam (9/21-8/22)
 Principal Investigator (9/22-12/23) 25% Ronald Hall (9/22-12/23)
 Li Li (1/24 – Present)
 Collaborators: Carlos Alvarez, PharmD, MSc, MSCS

5. Date: 8/20 Source: Merck & Co., Inc.
 Title: PCV13 and PPSV23 Utilization and Invasive Pneumococcal Disease Outcomes in Patients with Treated Rheumatoid Arthritis: A Population-based Cohort Study
 Role: Co-investigator % Effort: 5% PI: Carlos Alvarez
 Collaborators: Carlos Alvarez, PharmD, MSc, MSCS

6. Date: 9/19-11/20 Source: Medical Titan Group
 Title: Pharmacogenomics Rules Engine Optimization and Performance Assessments
 Total costs: \$275,000
 Role: Co-Principal Investigator % Effort: 40% PIs: Hall, La-Beck
 Collaborators: Irene La-Beck, PharmD, PhD, Amie Blasczyk, PharmD

7. Date: 1/16-1/21 Source: Cancer Prevention & Research Institute of Texas
 Title: North Texas Clinical Pharmacology Cancer Core
 Total costs: \$2,499,000
 Role: Co-investigator % Effort: 5% PI: Richard Leff
 Collaborators: Carlos Alvarez, PharmD , MSc, MSCS, Paul Trippier, PhD

8. Date: 5/16-2/21 Source: Merck & Co., Inc.
 Title: Pharmacokinetics of ceftolozane/tazobactam in patients with burns
 Total costs: \$126,770
 Role: Principal Investigator % Effort: 10% PI: Ronald Hall
 Collaborators: Steven Wolf, MD, Richard Leff, PharmD

9. Date: 1/14-12/14 Source: Laura W. Bush Institute for Women's Health
 Title: Effect of weight on doxorubicin pharmacokinetics and dosing in women with breast cancer
 Total costs: \$25,000
 Role: Principal Investigator % Effort: 25% PI: Ronald Hall
 Collaborators: Richard Leff, PharmD, David Euhus, MD

10. Date: 5/08-5/10 Source: NCCR CTSA Pilot Award program at UT Southwestern
 Title: Effect of body mass index on the pharmacokinetic variability of antifungal and antimycobacterial medications
 Total costs: \$77,000
 Role: Principal Investigator % Effort: 25% PI: Ronald Hall
 Collaborators: Richard Leff, PharmD, Mark Swancutt, MD, Tawanda Gumbo, MD

11. Date 7/06-6/09 Source: NCRR KL2
Title: North and Central Texas Clinical and Translational Science Initiative
Total costs: \$229,465
Role: Clinical Research Scholar % Effort: 75% PI: Milton Packer
12. Date: 9/04-9/05 Source: TTUHSC SOP seed grant program
Title: Piperacillin/tazobactam pharmacokinetics and pharmacodynamics in the obese patient
Total costs: \$5,000
Role: Principal Investigator % Effort: 10% PI: Ronald Hall
Collaborators: Sanjay Revankar, MD, Richard Leff, PharmD
13. Date: 4/03 Source: TTUHSC SOP equipment grant program
Title: Equipment grant proposal for a PM05 media pump
Total costs: \$6,500
Role: Co-investigator % Effort: 5% PI: Ronda Akins

Invited Presentations

National

1. **“Antifungal dosing in obesity”** at ID Week; Los Angeles, California, October 2024
2. **“Optimizing antibiotic dosing in obese patients”** at the American College of Clinical Pharmacy Annual Meeting; Austin, Texas, October 2010

Regional

3. **“Optimization of antimicrobial therapy”** Society of Critical Care Medicine – Texas Chapter; Dallas, Texas, October 2014
4. **“Pathways to a career in clinical or translational research”** Keynote Speaker at the St. Louis College of Pharmacy; St. Louis, Missouri, April 2014
5. **“Drug dosing in obesity: a search for answers”** Visiting Professor at Barnes-Jewish Hospital; St. Louis, Missouri, April 2014
6. **“Antimicrobial dosing in obesity: Does one size fit all?”** at the Metroplex Society of Health Systems Pharmacists Annual Meeting; Irving, Texas, January 2014
7. **“Clinical implications of dealing with drug shortages”** at the Texas Society of Health Systems Pharmacists Annual Meeting; Dallas, Texas, April 2012
8. **“Starting with the end in Mind: Empiric therapy for patients with hospital-acquired or healthcare-associated pneumonia”** at the Texas Society of Health Systems Pharmacists Annual Meeting; Austin, Texas, April 2009
9. **“Surviving the raging sea of antimicrobial resistance”** at the Texas Society of Health Systems Pharmacists Annual Meeting; Dallas, Texas, April 2008
10. **“New weapons of mass destruction against community-acquired pneumonia”** at the 9th Annual Infectious Diseases Pharmacotherapy Conference; San Antonio, Texas, November 2005

11. **“Management of problematic gram-negative pathogens”** at the Oklahoma Society of Health Systems Pharmacists Meeting; Oklahoma City, Oklahoma, April 2005
12. **“Antifungal therapy in the AD (after deoxycholate) era”** at the Texas Society of Health Systems Pharmacists 57th Annual Seminar; Austin, Texas, April 2005
13. **“Fluoroquinolone use: Is too much of a good thing a bad thing?”** at the Texas Society of Health Systems Pharmacists 56th Annual Seminar; Houston, Texas, April 2004

Academic Teaching

Texas Tech University Health Sciences Center, School of Pharmacy

1. Team Member, Advanced Infectious Diseases (PHAR 4226), Fall Semester 2023
2. Team Leader, Advanced Infectious Diseases (PHAR 4226), Fall Semester 2005-2022
3. Team Leader, Case Studies II (PHAR 3462), Fall Semester 2004
4. Team Member, Case Studies III (PHAR 4463), Spring Semester 2004, 2006, 2011
5. Lecturer, Drug Class Overview (PHAR 4204), Spring Semester 2003-2004
6. Team Member and Lecturer, Pharmacotherapy V – GI and Hepatic (PHAR3255), Spring Semester 2003-2004
7. Team Member and Lecturer, Pharmacotherapy III – Infectious Disorders (PHAR2351), Fall Semester 2002-2009
8. Team Member and Preceptor, Infectious Diseases (PHAR 4688, PHAR 4699), 2002-2007
9. Team Member and Preceptor, Internal Medicine (PHAR 4675), 2002-2007
10. Team Member and Preceptor, Inpatient Clinical Skills (PHAR 4276), 2002-2006

University of Texas Southwestern Medical School

1. Invited Lecturer, Clinical Pharmacology (DCS 5203), 2009-2011
2. Invited Lecturer, Core Curriculum Course for Pediatric Infectious Diseases Fellows, 2006-2009
3. Invited Lecturer, Core Curriculum Course for Infectious Diseases Fellows, 2003-2005

Pharmacy Resident Teaching (2002-2007)

1. Preceptor, Texas Tech University Health Sciences Center Infectious Diseases, Critical Care, and Pharmacotherapy residency programs; Infectious Diseases, Antibiotic Management, & Research
2. Preceptor, Dallas Veterans Affairs Medical Center Pharmacy Practice residency program; Infectious Diseases, Internal Medicine

Previous Academic and Pharmacy Practice Experience

- 10/17-8/22 **Vice-Chair of Research**
Department of Pharmacy Practice
Texas Tech University Health Sciences Center
Jerry H. Hodge School of Pharmacy
Dallas, Texas
- 6/17 – 9/17 **Acting Division Head**
Clinical and Translational Science Division
Texas Tech University Health Sciences Center, School of Pharmacy
Dallas, Texas
- 5/17 – 5/20 **Adjunct Assistant Professor**
Department of Surgery
University of Texas Southwestern
Dallas, Texas
- 5/14 – 5/17 **Adjunct Assistant Professor**
Department of Internal Medicine, Division of Hematology/Oncology
University of Texas Southwestern
Dallas, Texas
- 5/13-8/22 **Member**
Clinical Pharmacology & Experimental Therapeutics Center
Texas Tech University Health Sciences Center
Jerry H. Hodge School of Pharmacy
Dallas, Texas
- 8/09 – 5/14 **Adjunct Assistant Professor**
Department of Clinical Sciences, Division of Pharmacology
University of Texas Southwestern
Dallas, Texas
- 7/06 – 6/09 **National Institutes of Health Clinical Research Scholar**
University of Texas Southwestern, Graduate School of Biomedical Sciences
Dallas, Texas
- 4/06 – 8/09 **Assistant Professor of Pharmacy Practice**
Clinical Sciences and Research Division
Texas Tech University Health Sciences Center, School of Pharmacy
Dallas, Texas
- 7/04 – 7/06 **Program Director**
ASHP Accredited Infectious Diseases Specialty Residency
Texas Tech University Health Sciences Center, School of Pharmacy
- 8/02 – 7/07 **Advanced Practice Pharmacist – Infectious Diseases**
Veterans Affairs North Texas Health Care System

Dallas, Texas

8/02 – 4/06

Assistant Professor of Pharmacy Practice
Division of Internal Medicine
Texas Tech University Health Sciences Center

7/01- 6/02

Clinical Instructor
College of Pharmacy - Department of Pharmacology
University of Texas at Austin and University of Texas Health Science Center at San Antonio

Honors and Awards

2020-2021

Texas Tech University Health Sciences Center
One Team Fellows Program (Leadership development program)
Competitive application; one of 40 Fellows selected to participate

2019

Texas Tech University Health Sciences Center
Values Coin – Beyond Service
Presented by President Tedd Mitchell, MD

2017-2018

Mentoring Excellence for Developing Leaders program
Center for Translational Medicine
University of Texas Southwestern Medical Center

2016

Focused Investigator Training (FIT) program
American College of Clinical Pharmacy
Selected through a competitive application process

2008

Young Alumni of the Year, St. Louis College of Pharmacy

2007

2006 Texas Tech University Health Sciences Center, School of Pharmacy
P2 Teaching Team of the Year (Infectious Diseases)

Professional Service

American College of Clinical Pharmacy

- Infectious Diseases PRN Research Committee (9/18 – 8/19)
- Credentialing Committee (9/04 – 8/05)

Dallas/Fort Worth College of Clinical Pharmacy

- **President** (6/06 – 6/07)
- **Treasurer** (3/03 – 12/04)

Infectious Diseases Society of America

- ID Week Abstract Reviewer (2023)
- ID Week Abstract Appreciation Program Member (2023)

Kappa Psi Pharmaceutical Fraternity

- Province VII Historian (3/99 – 4/01)

Phi Lambda Sigma – Pharmacy Leadership Society

- Chapter President (12/98 – 12/99)

Regulatory Affairs Professionals Society

Society of Infectious Diseases Pharmacists

- Strategic Planning Committee (9/23 – Present)
- Guidelines Committee (9/22 – 8/23)
- Research Committee (9/17 – 8/19)
- Antimicrobial Dosing in Obesity Task Force (11/14 – 10/15)
- Interorganizational Committee (9/13 – 8/14)
- Program Committee (9/13 – 8/14)
- Annual Report Committee (9/11 – 8/12)
- Recognition Awards Committee (9/11 – 8/12)
- Program Committee (11/10 – 9/11)
- **Chair** – Internet Committee (9/07 – 9/09)
- Strategic Planning Taskforce (9/07 – 3/08)
- Newsletter Committee (9/06 – 9/09)
- **Chair** - Elections Committee (9/05 – 9/06)
- Membership Committee (9/03 – 9/05)

Texas Society of Health-Systems Pharmacists

- Educational Affairs Committee (5/08 – 5/09)
- Professional Affairs Committee (5/05 – 5/06)

Scientific Reviewer - Grants

ASHP Foundation's Pharmacy Resident Practice-Based Research Grant
SIDP Young Investigator Grant

Scientific Reviewer - Manuscripts

Report available upon request

Academic Service

Health Sciences Center

9/25 – Present	Faculty Senator (elected by Pharmacy Practice faculty)
7/24	President's Excellence in Research Award Committee
1/23 – Present	Chair - Institutional Review Board #2
9/22 – Present	Member – Institutional Review Board #2
7/23	President's Early Career Investigator Award Committee
2/22 – 5/23	Health Disparities Research Subcommittee
9/19 – 8/21	Senior Vice-President of Research and Innovation Search Committee
6/17 – Present	Clinical Research Institute Advisory Committee - Seed Grant Review Subcommittee 11/17-1/18

Jerry H. Hodge School of Pharmacy

Current

- 1/23 – Present Dean’s Research Council
- 9/17 – Present Research Advisory Committee (Ex-officio)

Previous appointments

- 1/25 **Chair** – Mid-probationary Review Committee
- 10/22 – 8/23 **Chair** – Pharmacy Practice Tenure-Track Faculty Search Committee
- 9/15 – 8/23 Faculty Affairs Committee (elected by Pharmacy Practice faculty)
- 9/17 – 8/18 **Chair** - Faculty Affairs Committee (elected by Faculty Affairs Committee)
- 9/16 – 8/18 School of Pharmacy Honor Council
- 9/14 – 11/14 **Chair** – Mid-probationary Review Committee
- 9/13 – 3/14 Clinical & Translational Research Tenure Track Faculty Search Committee
- 9/13 – 11/13 Mid-probationary Review Committee
- 7/13 – 3/14 Pharmacy Practice Department Chair Search Committee
- 9/11 – 8/14 Research Advisory Committee
- 10/09 – 9/10 Faculty Affairs Committee (elected by Pharmacy Practice faculty)
- 9/09 – 5/10 Ad Hoc Clinical Simulation Center and Assessment Committee
- 9/09 – 9/10 **Chair** - Student Outcomes Assessment Committee
- 5/08 – 9/09 Chair-Elect - Student Outcomes Assessment Committee
- 3/08 – 4/08 Ad Hoc Student/Faculty Advising Committee
- 7/05 – 9/05 Ad Hoc Intradepartmental Communications Committee
- 10/04 Judge - Clinical Skills Competition, Texas Tech University HSC
- 6/04 – 5/06 Faculty Affairs Committee (elected by Pharmacy Practice faculty)
- 5/04 Environmental Scanning Committee
- 8/03 **Chair** - Ad hoc Student Recruitment Planning for DFW Campus Expansion

8/02 – 6/04

Ad hoc Technology Committee